Hang Quach

Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells

RE Cooke, KM Quinn, H Quach, S Harrison, HM Prince, R Koldej, D Ritchie

Journal article  |  2020  |  Frontiers in Immunology

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Herve Avet-Loiseau, Tomer M Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay Nooka, Hang Quach, Markus Munder, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, et al.

Journal article  |  2020  |  Journal of Hematology & Oncology

BACKGROUND: Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/d..

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Meletios Dimopoulos, Hang Quach, Maria-Victoria Mateos, Ola Landgren, Xavier Leleu, David Siegel, Katja Weisel, Hui Yang, Zandra Klippel, Anita Zahlten-Kumeli, Saad Z Usmani

Journal article  |  2020  |  The Lancet

BACKGROUND: Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relaps..

Perspectives in the Rapidly Evolving Treatment Landscape of Multiple Myeloma: Expert Review of New Data Presentations from ASH 2019.

Chng Wee Joo, Hang Quach, Noopur Raje

Journal article  |  2020  |  Clinical Lymphoma Myeloma and Leukemia

The number and type of therapeutic options available to treat patients with multiple myeloma has risen dramatically over recent ye..

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic

Pietro Di Ciaccio, Georgia McCaughan, Judith Trotman, Phoebe Joy Ho, Chan Y Cheah, Shane Gangatharan, Joel Wight, Matthew Ku, Hang Quach, Robin Gasiorowski, Mark N Polizzotto, Henry Miles Prince, Stephen Mulligan, Constantine S Tam, Gareth Gregory, Greg Hapgood, Andrew Spencer, Michael Dickinson, Maya Latimer, Anna Johnston, et al.

Journal article  |  2020  |  Internal Medicine Journal

The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known ..

Patient-reported outcome measures in multiple myeloma: Real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial

Elizabeth M Moore, Tracy A King, Erica M Wood, Rasa Ruseckaite, Daniela Klarica, Andrew Spencer, P Joy Ho, Hang Quach, H Miles Prince, Zoe K McQuilten

Journal article  |  2020  |  American Journal of Hematology

Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma

Andrew Davies, Peter Trask, Judit Demeter, Axel Florschuetz, Mathias Haenel, Tomohiro Kinoshita, Ruth Pettengell, Hang Quach, Stephen Robinson, Shalal Sadullah, Juan-Manuel Sancho, Miklos Udvardy, Mathias Witzens-Harig, Andrea Knapp, Wenxin Liu

Journal article  |  2020  |  Annals of Hematology

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola Abdallah, Natalie Callander, Nikoletta Lendvai, Douglas Sborov, Attaya Suvannasankha, Katja Weisel, Lionel Karlin, Edward Libby, Bertrand Arnulf, Thierry Facon, Cyrille Hulin, K Martin Kortum, Paula Rodriguez-Otero, Saad Z Usmani, et al.

Journal article  |  2020  |  The Lancet Oncology

BACKGROUND: Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activit..

Carfilzomib, Thalidomide and Dexa-methasone (KTd) is safe and effective in RRMM: interim analysis of the single arm, multicentre phase II ALLG MM018/AMN002 study

Slavisa Ninkovic, Wee Joo Chng, Simon J Harrison, Nick Murphy, Jae Hoon Lee, Jane Estell, Noemi Horvath, Richard Eek, Bradley Augustson, Akash Kalro, Rajeev Rajagopal, Kihyun Kim, Soo-Mee Bang, Shang-Yi Huang, Belinda Butcher, Brian Durie, Peter Mollee, Hang Quach

Conference Proceedings  |  2019  |  Clinical Lymphoma Myeloma and Leukemia

Patient Reported Outcome Measures in multiple myeloma: real-time rePorTing to improve care (My-PROMPT) - a pilot randomised controlled trial

Elizabeth Moore, Tracy King, P Joy Ho, Daniela Klarica, H Miles Prince, Hang Quach, Rasa Ruseckaite, Alicia Snowden, Andrew Spencer, Erica Wood, Zoe McQuilten

Conference Proceedings  |  2019  |  Clinical Lymphoma Myeloma and Leukemia

Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Hilary Blacklock, Elizabeth Moore, Cameron Wellard, Simon J Harrison, P Joy Ho, Jay Hocking, Zoe McQuilten, Peter Mollee, Hang Quach, Ruth Spearing, Erica Wood, Andrew Spencer

Conference Proceedings  |  2019  |  Clinical Lymphoma Myeloma and Leukemia

Cell surface glucose-regulated protein 78 (GRP78) is upregulated in plasma cells of patients with multiple myeloma compared to monoclonal gammopathy of uncertain significance

Slavisa Ninkovic, Lenny Straszkowski, Anupa Dey, Constantine Tam, Harshal Nandurkar, Simon J Harrison, Louise Purton, Hang Quach

Conference Proceedings  |  2019  |  Clinical Lymphoma Myeloma and Leukemia

Utilisation of liquid biopsies in functional high-risk myeloma demonstrates a unique mutational pattern and extensive spatial heterogeneity

Andrew Spencer, Kawa Choi, Malgorzata Gorniak, Hang Quach, Noemi Horvath, Ian Kerridge, Edwin Lee, Edward Morris, Flora Yuen, Anna Kalff, Krystal Bergin, Tiffany Khong, Sridurga Mithraprabhu

Conference Proceedings  |  2019  |  Clinical Lymphoma Myeloma and Leukemia

Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction

Peter Mollee, Stephen Boyle, Cameron Wellard, Elizabeth Moore, Hilary Blacklock, Simon J Harrison, P Joy Ho, Jay Hocking, Zoe McQuilten, Hang Quach, Ruth Spearing, Erica Wood, Andrew Spencer

Conference Proceedings  |  2019  |  CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma

Sumita Ratnasingam, Joshua Casan, Jake Shortt, Eliza Hawkes, Michael Gilbertson, Zoe McQuilten, George Grigoriadis, Kay Thwe Htun, Swe Myo Htet, Philip Campbell, Khai Li Chai, Hang Quach, Sushrut Patil, Stephen Opat

Journal article  |  2019  |  Scientific Reports

The role of cytarabine-based induction and autologous stem cell transplantation (ASCT) in front-line treatment of younger patients..

Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry

P Joy Ho, Elizabeth M Moore, Zoe K McQuilten, Cameron Wellard, Krystal Bergin, Bradley Augustson, Hilary Blacklock, Simon J Harrison, Noemi Horvath, Tracy King, Peter Mollee, Hang Quach, Christopher Reid, Brian Rosengarten, Patricia Walker, Erica M Wood, Andrew Spencer

Journal article  |  2019  |  Clinical Lymphoma Myeloma and Leukemia

BACKGROUND: Renal impairment (RI) is a common complication of multiple myeloma (MM) and remains a poor prognostic factor despite i..

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, H Nahi, C Hulin, H Quach, H Goldschmidt, M O'Dwyer, A Perrot, CP Venner, K Weisel, JR Mace, N Raje, M Attal, M Tiab, M Macro, et al.

Journal article  |  2019  |  New England Journal of Medicine

Phase I/II, open-label, 2-arm study to evaluate safety, tolerability, and clinical activity of GSK2857916 in combination with 2 standard-of-care (SoC) regimens in relapsed/refractory multiple myeloma: (DREAMM 6).

Luciano J Costa, Hang Quach, Keith Stockerl-Goldstein, Bradley Augustson, Geraldine Ferron-Brady, Bikramjit Chopra, Allie Moore, Sophia Hudson, Jiangxiu Zhou, Veronique Bragulat, Mala Kiran Talekar, Joanna Opalinska

Conference Proceedings  |  2019  |  JOURNAL OF CLINICAL ONCOLOGY

Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA.

Saad Zafar Usmani, Thierry Facon, Shaji Kumar, Torben Plesner, Philippe Moreau, Supratik Basu, Hareth Nahi, Margaret Macro, Hang Quach, Aurore Perrot, Chris Venner, Katja Weisel, Noopur S Raje, Michel Attal, Xavier Leleu, Maria Krevvata, Jianping Wang, Rachel Kobos, Cyrille Hulin

Conference Proceedings  |  2019  |  JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.

Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Herve Avet-Loiseau, Tomer M Mark, Ivan Spicka, Alberto Bosi, Vania TM Hungria, Michele Cavo, Je-Jung Lee, Ajay K Nooka, Hang Quach, Markus Munder, Meral Beksac, Pieter Sonneveld, David Soong, Jon Ukropec, Ming Qi, Maria-Victoria Mateos

Conference Proceedings  |  2019  |  JOURNAL OF CLINICAL ONCOLOGY

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven Horwitz, Owen A O'Connor, Barbara Pro, Tim Illidge, Michelle Fanale, Ranjana Advani, Nancy L Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Arpad Illes, Kensei Tobinai, Kunihiro Tsukasaki, Su-Peng Yeh, Andrei Shustov, et al.

Journal article  |  2019  |  The Lancet

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Herve Avet-Loiseau, Tomer M Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay K Nooka, Hang Quach, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Emma C Scott, et al.

Journal article  |  2018  |  HAEMATOLOGICA

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Thierry Facon, Shaji K Kumar, Torben Plesner, Robert Z Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P Venner, Katja Weisel, Joseph R Mace, Tahamtan Ahmadi, Christopher Chiu, Jianping Wang, Rian Van Rampelbergh, et al.

Conference Proceedings  |  2018  |  Blood

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: Preliminary Outcome from the Open Label Phase II ALLGMM018/AMN003 Study

Hang Quach, Simon J Harrison, Slavisa Ninkovic, Jane Estell, Noemi Horvath, Nick Murphy, Richard Eek, Bradley Augustson, Philip Campbell, Rajeev Rajagopal, Akash Kalro, Robyn Hemme, Belinda Butcher, Tracey Gerber, Peter Mollee, Brian GM Durie, Wee-Joo Chng

Conference Proceedings  |  2018  |  Blood

Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Andrew Spencer, Hang Quach, Noemi Horvath, Ian H Kerridge, Flora Yuen, Edwin Sze-Hung Lee, Edward S Morris, Anna Kalff, Krystal Bergin, Shreerang Sirdesai, Malgorzata Gorniak, Sridurga Mithraprabhu, Tiffany Khong, John Reynolds

Conference Proceedings  |  2018  |  Blood

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.

Judith Trotman, Sally F Barrington, David Belada, Michel Meignan, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Günter R Fingerle-Rowson, Jiawen Zhu, Tina Nielsen, Deniz Sahin, Wolfgang Hiddemann, Robert E Marcus, Andrew Davies, undefined PET investigators from the GALLIUM study

Journal article  |  2018  |  The Lancet Oncology

BACKGROUND: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progres..

Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naive patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies

Tadeusz Robak, Jan A Burger, Alessandra Tedeschi, Paul M Barr, Carolyn Owen, Osnat Bairey, Peter Hillmen, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen McCarthy, Steven E Coutre, Hang Quach, Gianluca Gaidano, Zvenyslava Maslyak, Don A Stevens, Carol Moreno, Devinder S Gill, Ian W Flinn, John G Gribben, et al.

Journal article  |  2018  |  AMERICAN JOURNAL OF HEMATOLOGY

Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma

Nicholas A Gherardin, Liyen Loh, Lorenztino Admojo, Alexander J Davenport, Kelden Richardson, Amy Rogers, Phillip K Darcy, Misty R Jenkins, H Miles Prince, Simon J Harrison, Hang Quach, David P Fairlie, Katherine Kedzierska, James McCluskey, Adam P Uldrich, Paul J Neeson, David S Ritchie, Dale I Godfrey

Journal article  |  2018  |  SCIENTIFIC REPORTS

Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

Hang Quach, Simon Benson, Helen Haysom, Anne-Marie Wilkes, Nicole Zacher, Merrole Cole-Sinclair, Henry Miles Prince, Peter Mollee, Andrew Spencer, Phoebe Joy Ho, Simon J Harrison, Cindy Lee, Bradley Augustson, James Daly

Journal article  |  2018  |  Internal Medicine Journal

"Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma

Ashleigh Scott, Nicholas Weber, Campbell Tiley, Kerry Taylor, John Taper, Simon Harrison, Kah-Lok Chan, Richard Stark, Cindy Lee, Kirk Morris, P Joy Ho, Anthony Dodds, Sundra Ramanathan, Raj Ramakrishna, Anne-Marie Watson, Bradley Auguston, Fiona Kwok, Hang Quach, Pauline Warburton, Philip Rowlings, et al.

Journal article  |  2018  |  Leukemia & Lymphoma

Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison

Tadeusz Robak, Jan A Burger, Alessandra Tedeschi, Paul M Barr, Carolyn Jane Owen, Osnat Bairey, Peter Hillmen, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen McCarthy, Steven Coutre, Quach Hang, Gianluca Gaidano, Zvenyslava Maslyak, Don A Stevens, Carol Moreno, Devinder Gill, Ian W Flinn, John Gribben, et al.

Conference Proceedings  |  2017  |  BLOOD

Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial

Robert J Pelham, Xuguang Hu, Philippe Moreau, Albert Oriol, Hang Quach, Tibor Kovacsovics, Jonathan J Keats, Shibao Feng, Amy S Kimball, Meletios A Dimopoulos

Conference Proceedings  |  2017  |  BLOOD

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor

Suzanne Lentzsch, Hang Quach, Asher A Chanan-Khan, Noemi Horvath, Marcelo Capra, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Piruntha Thiyagarajah, Himal Amin, Tineke Casneuf, Pieter Sonneveld, Jordan Schecter, Vania TM Hungria

Conference Proceedings  |  2017  |  BLOOD

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

Constantine S Tam, Quach Hang, Andrew Nicol, Xavier Badoux, Hannah Rose, H Miles Prince, Michael F Leahy, Richard Eek, Nicholas Wickham, Sushrut S Patil, Jane Huang, Xiaoping Zhang, Lai Wang, Eric Hedrick, William Novotny, Ian W Flinn

Conference Proceedings  |  2017  |  BLOOD

Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd

Timothy P Hughes, Eduardo Munhoz, Marco Aurelio Salvino, Tee Chuan Ong, Alaa Elhaddad, Jake Shortt, Hang Quach, Carolina Pavlovsky, Vernon J Louw, Lee-Yung Shih, Anna G Turkina, Luis Meillon, Yu Jin, Sandip Acharya, Darshan Dalal, Jeffrey H Lipton

Journal article  |  2017  |  British Journal of Haematology

Bisphosphonate guidelines for treatment and prevention of myeloma bone disease

Oi Lin Lee, Noemi Horvath, Cindy Lee, Doug Joshua, Joy Ho, Jeff Szer, Hang Quach, Andrew Spencer, Simon Harrison, Peter Mollee, Andrew W Roberts, Dipti Talaulikar, Ross Brown, Bradley Augustson, Silvia Ling, Wilfrid Jaksic, John Gibson, Anna Kalff, Anna Johnston, Akash Kalro, et al.

Journal article  |  2017  |  Internal Medicine Journal

RENAL IMPAIRMENT IN MYELOMA - PATIENT CHARACTERISTICS, TREATMENT MODALITIES, STEM CELL TRANSPLANT & OUTCOMES FROM THE AUSTRALIAN AND NEW ZEALAND MYELOMA REGISTRY

PJ Ho, E Moore, Z McQuilten, K Bergin, B Augustson, H Blacklock, N Horvath, T King, J McNeil, P Mollee, H Quach, C Reid, B Rosengarten, P Walker, E Wood, A Spencer

Conference Proceedings  |  2017  |  HAEMATOLOGICA

POMALIDOMIDE ALONE OR IN COMBINATION WITH LOW DOSE DEXAMETHASONE AS MAINTENANCE FOLLOWING INDUCTION WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE IN RELAPSED AND REFRACTORY MYELOMA (ALLG MM14)

A Kalff, N Kennedy, J Reynolds, H Quach, PJ Ho, N Horvath, P Mollee, J D'Rozario, K Taylor, J Estell, A Spencer

Conference Proceedings  |  2017  |  HAEMATOLOGICA

Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study

Hang Quach, Darrell White, Andrew Spencer, P Joy Ho, Divaya Bhutani, Mike White, Sandeep Inamdar, Chris Morris, Ying Ou, Martin Gyger

Journal article  |  2017  |  CANCER CHEMOTHERAPY AND PHARMACOLOGY

Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.

Katja C Weisel, Jesus San Miguel, Gordon Cook, Merav Leiba, Kenshi Suzuki, Shaji Kumar, Michele Cavo, Herve Avet-Loiseau, Hang Quach, Vania Hungria, Suzanne Lentzsch, Roman Hajek, Pieter Sonneveld, Kaida Wu

Conference Proceedings  |  2017  |  Journal of Clinical Oncology

Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR).

Suzanne Lentzsch, Katja C Weisel, Maria-Victoria Mateos, Vania Hungria, Markus Munder, Ajay K Nooka, Tomer Mark, Hang Quach, Emma Catherine Scott, Je-Jung Lee, Pieter Sonneveld, Tineke Casneuf, Christopher Chiu, Xiang Qin, Himal Amin, Piruntha Thiyagarajah, Jordan Mark Schecter, Ming Qi, Andrew Spencer

Conference Proceedings  |  2017  |  Journal of Clinical Oncology

Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study

Hang Quach, Liam Fernyhough, Ross Henderson, Gillian Corbett, Bart Baker, Peter Browett, Hilary Blacklock, Cecily Forsyth, Craig Underhill, Paul Cannell, Judith Trotman, Annette Neylon, Simon Harrison, Emma Link, Arlene Swern, Linda Cowan, Meletios A Dimopoulos, H Miles Prince

Journal article  |  2017  |  British Journal of Haematology

Rates of Upfront Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM): A report from the MRDR

Krystal Bergin, Elizabeth Moore, Zoe McQuilten, Bradley Augustson, Hilary Blacklock, James D'Rozario, Michael Dickinson, Jane Estell, P Joy Ho, Simon He, Jay Hocking, Noemi Horvath, Tracy King, Teresa Leung, John McNeil, Luke Merriman, Peter Mollee, H Miles Prince, Hang Quach, Sundra Ramanathan, et al.

Conference Proceedings  |  2017  |  CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Maturing Data from the Australia and New Zealand Myeloma and Related Diseases Registry

Elizabeth Moore, Zoe McQuilten, Krystal Bergin, Bradley Augustson, Hilary Blacklock, James D'Rozario, Michael Dickinson, Jane Estell, P Joy Ho, Simon He, Jay Hocking, Noemi Horvath, Tracy King, Teresa Leung, John McNeil, Luke Merriman, Peter Mollee, H Miles Prince, Hang Quach, Sundra Ramanathan, et al.

Conference Proceedings  |  2017  |  CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Treatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Dipti Talaulikar, Constantine S Tam, Douglas Joshua, Joy Phoebe Ho, Jeff Szer, Hang Quach, Andrew Spencer, Simon Harrison, Peter Mollee, Andrew W Roberts, Noemi Horvath, Cindy Lee, Andrew Zannettino, Ross Brown, Bradley Augustson, Wilfrid Jaksic, John Gibson, Anna Kalff, Anna Johnston, Judith Trotman, et al.

Journal article  |  2017  |  Internal Medicine Journal

A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy

Anna Kalff, Sridurga Mithraprabhu, Tiffany T Khong, Malarmathy Ramachandran, Kate Reed, Hang Quach, Patricia A Walker, Krystal Bergin, Andrew Spencer

Conference Proceedings  |  2016  |  Blood

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor

Asher A Chanan-Khan, Suzanne Lentzsch, Hang Quach, Noemi Horvath, Marcelo Capra, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Ming Qi, William Deraedt, Jordan Schecter, Himal Amin, Xiang Qin, Tineke Casneuf, Christopher Chiu, A Kate Sasser, Pieter Sonneveld

Conference Proceedings  |  2016  |  Blood

An Open-Label, Single-Arm, Phase 1 Study of the Pharmacokinetics (PK) and Safety of Carfilzomib in Patients with Relapsed Multiple Myeloma and End-Stage Renal Disease (ESRD)

Hang Quach, Darrell White, Andrew Spencer, P Joy Ho, Divaya Bhutani, Mike White, Sandeep Inamdar, Chris Morris, Ying Ou, Martin Gyger

Conference Proceedings  |  2016  |  Blood

Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group (vol 45, pg 94, 2015)

H Quach, D Joshua, J Ho, J Szer, A Spencer, SJ Harrison, P Mollee, AW Roberts, N Horvath, D Talulikar, B To, A Zannettino, R Brown, L Catley, B Augustson, W Jaksic, J Gibson, HM Prince

Journal article  |  2016  |  Internal Medicine Journal

Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry

Krystal Bergin, Elizabeth Moore, Zoe McQuilten, Erica Wood, Bradley Augustson, Hilary Blacklock, Joy Ho, Noemi Horvath, Tracy King, John McNeil, Peter Mollee, Hang Quach, Christopher M Reid, Brian Rosengarten, Patricia Walker, Andrew Spencer

Journal article  |  2016  |  BMC Medical Research Methodology

BACKGROUND: Plasma cell dyscrasias (PCD) are a spectrum of disorders resulting from the clonal expansion of plasma cells, ranging ..

T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments

Edwin D Hawkins, Delfim Duarte, Olufolake Akinduro, Reema A Khorshed, Diana Passaro, Malgorzata Nowicka, Lenny Straszkowski, Mark K Scott, Steve Rothery, Nicola Ruivo, Katie Foster, Michaela Waibel, Ricky W Johnstone, Simon J Harrison, David A Westerman, Hang Quach, John Gribben, Mark D Robinson, Louise E Purton, Dominique Bonnet, et al.

Journal article  |  2016  |  NATURE

Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma

Rachel E Cooke, Nicholas A Gherardin, Simon J Harrison, Hang Quach, Dale I Godfrey, Miles Prince, Rachel Koldej, David S Ritchie

Journal article  |  2016  |  JOURNAL OF TRANSLATIONAL MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, Ajay K Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania Hungria, Markus Munder, Maria V Mateos, Tomer M Mark, Ming Qi, Jordan Schecter, Himal Amin, Xiang Qin, William Deraedt, Tahamtan Ahmadi, Andrew Spencer, Pieter Sonneveld

Journal article  |  2016  |  New England Journal of Medicine

Background: Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and ..

Myeloma of the central nervous system - an ongoing conundrum!

Simon J Harrison, Andrew Spencer, Hang Quach

Journal article  |  2016  |  Leukemia & Lymphoma

Haemolytic crisis in G6PD-deficiency triggered by recreational use of synthetic cannabis

Amy J Halliday, Khai Li Chai, Kate H Hurley, Slavisa Ninkovic, Aaron Bloch, Hang Quach

Journal article  |  2016  |  Case Reports in Internal Medicine

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common inherited cause of haemolytic anaemia. Recognition and avoi..

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, P Hillmen, NL Bartlett, J Li, D Simpson, S Grosicki, S Devereux, H McCarthy, S Coutre, H Quach, G Gaidano, Z Maslyak, DA Stevens, A Janssens, et al.

Journal article  |  2015  |  New England Journal of Medicine

High GRP78 (78-kDa Glucose-Regulated Protein) Expression Predicts for a Favorable Clinical Outcome in Patients with Multiple Myeloma and May be a Potentially Useful Therapeutic Target in the Treatment of Multiple Myeloma

Hang Quach, Daniel North, Susanna Freddi, Shuh Y Tan, Lenny Straszkowski, Harshal Nandurkar

Conference Proceedings  |  2015  |  BLOOD

Comment on "Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma"

Simon J Harrison, Hang Quach, Andrew Spencer, H Miles Prince

Journal article  |  2015  |  Haematologica

Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma

Kah-Lok Chan, Robin Filshie, Harshal Nandurkar, Hang Quach

Journal article  |  2015  |  Leukemia & Lymphoma

Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group (vol 45, pg 335, 2015)

H Quach, D Joshua, J Ho, J Szer, A Spencer, S Harrison, P Mollee, A Roberts, N Horvath, D Talaulikar, B To, A Zannettino, R Brown, L Catley, B Augustson, W Jaksic, J Gibson, HM Prince

Journal article  |  2015  |  Internal Medicine Journal

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

Simon J Harrison, Hang Quach, Emma Link, Huaibao Feng, Joanne Dean, Michael Copeman, Helgi Van de Velde, Anthony Schwarer, Bartrum Baker, Andrew Spencer, John Catalano, Philip Campbell, Bradley Augustson, Ken Romeril, Henry Miles Prince

Journal article  |  2015  |  American Journal of Hematology

Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

N Weber, P Mollee, B Augustson, R Brown, L Catley, J Gibson, S Harrison, PJ Ho, N Horvath, W Jaksic, D Joshua, H Quach, AW Roberts, A Spencer, J Szer, D Talaulikar, B To, A Zannettino, HM Prince

Journal article  |  2015  |  Internal Medicine Journal

Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group

H Quach, D Joshua, J Ho, J Szer, A Spencer, S Harrison, P Mollee, AW Roberts, N Horvath, D Talaulikar, B To, A Zannettino, R Brown, L Catley, B Augustson, W Jaksic, J Gibson, HM Prince

Journal article  |  2015  |  Internal Medicine Journal

Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

H Quach, D Joshua, J Ho, J Szer, A Spencer, SJ Harrison, P Mollee, AW Roberts, N Horvath, D Talulikar, B To, A Zannettino, R Brown, L Catley, B Augustson, W Jaksic, J Gibson, HM Prince

Journal article  |  2015  |  Internal Medicine Journal

Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration

A Arumugaswamy, S He, H Quach, J Brotchie, A Grigg

Journal article  |  2014  |  Internal Medicine Journal

Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy

AC Chan, P Neeson, E Leeansyah, K Tainton, H Quach, HM Prince, SJ Harrison, DI Godfrey, D Ritchie, SP Berzins

Journal article  |  2014  |  CLINICAL AND EXPERIMENTAL IMMUNOLOGY

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid (R)) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial

Franck Morschhauser, Olivier Fitoussi, Corinne Haioun, Catherine Thieblemont, Hang Quach, Richard Delarue, Sylvie Glaisner, Jean Gabarre, Andre Bosly, John Lister, Ju Li, Bertrand Coiffier

Journal article  |  2013  |  European Journal of Cancer

Radiotherapy in orbital lymphoma: optimizing the backbone to build upon

Hang Quach, Sidney Davis

Journal article  |  2013  |  Leukemia & Lymphoma

Lenalidomide in multiple myeloma: Current status and future potential

Hang Quach, Anna Kalff, Andrew Spencer

Journal article  |  2012  |  American Journal of Hematology

Successful use of eltrombopag without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia

Hang Quach, Lai-yang Lee, Brodie Smith, Tony Korman, Ian J Woolley

Journal article  |  2012  |  AIDS

DEREGULATION OF SIRTUINS PRESENTS IT AS NOVEL THERAPEUTIC TARGETS IN MYELOMA

S Mithraprabhu, A Kalff, H Quach, T Khong, A Andrew

Conference Proceedings  |  2012  |  HAEMATOLOGICA

HISTONE DEACETYLASE INHIBITOR INDUCED ANTI-MYELOMA ACTIVITY IS MEDIATED PRINCIPALLY VIA CLASS I DEACETYLASE INHIBITION

S Mithraprabhu, A Kalff, H Quach, T Khong, A Andrew

Conference Proceedings  |  2012  |  HAEMATOLOGICA

Serum protein electrophoresis: a precautionary tale

George Grigoriadis, Jake Shortt, Hang Quach, Stephen Opat

Journal article  |  2012  |  Pathology

Deactylases in multiple myeloma: Expression, inhibition and resistance to inhibition

Sridurga Mithraprabhu, Anna Kalff, Hang Quach, Andrew Spencer

Conference Proceedings  |  2012  |  Experimental and Molecular Therapeutics

Response Dexamethasone dose alters expression of NK activating receptors in vivo

Andy Hsu, Hang Quach, Tsin Tai, H Miles Prince, Simon J Harrison, Joseph A Trapani, Mark J Smyth, Paul J Neeson, David S Ritchie

Journal article  |  2011  |  Blood

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

Simon J Harrison, Hang Quach, Emma Link, John F Seymour, David S Ritchie, Sam Ruell, Joanne Dean, Henry Januszewicz, Ricky Johnstone, Paul Neeson, Michael Dickinson, Jean Nichols, H Miles Prince

Journal article  |  2011  |  Blood

Failure of eculizumab to correct paroxysmal cold hemoglobinuria

Gareth Peter Gregory, Stephen Opat, Hang Quach, Jake Shortt, Tran Huyen

Journal article  |  2011  |  Annals of Hematology

Reversal of Transfusion Dependence by Tumor Necrosis Factor Inhibitor Treatment in a Patient With Concurrent Rheumatoid Arthritis and Primary Myelofibrosis

Anderson Ong, Hang Quach, Michelle Leech

Journal article  |  2011  |  Journal of Clinical Rheumatology

Managing multiple myeloma in the elderly: are we making progress?

Hang Quach, H Miles Prince, Andrew Spencer

Journal article  |  2011  |  Expert Review of Hematology

CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME - A DIFFICULT DIAGNOSTIC AND MANAGEMENT ISSUE

N Chan, S Brown, H Tran, S Chunilal, H Quach, S Opat

Conference Proceedings  |  2011  |  INTERNAL MEDICINE JOURNAL

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

Andy K Hsu, Hang Quach, Tsin Tai, H Miles Prince, Simon J Harrison, Joseph A Trapani, Mark J Smyth, Paul Neeson, David S Ritchie

Journal article  |  2011  |  Blood

Extra-nasal NK/T cell lymphoma masquerading as renal infarction

Mun Sem Liew, Andrea M Chan, Stuart Galloway, Giulio Comin, Brendan Flaim, H Miles Prince, Hang Quach

Journal article  |  2010  |  Leukemia and Lymphoma

Bortezomib and dexamethasone from cycle 1 as treatment and maintenance for multiple myeloma relapse (The BoMeR trial): Impact on response and time to progression

SJ Harrison, H Quach, J Dean, A Milner, MC Copeman, HM Prince

Conference Proceedings  |  2010  |  Journal of Clinical Oncology

Natural killer cell function in multiple myeloma is impaired by dexamethasone and can not be rescued by immunomodulatory drugs

Andy Hsu, Hang Quach, Tsin Tai, HM Prince, Mark J Smyth, Joseph A Trapani, Paul J Neeson, David S Ritchie

Conference Proceedings  |  2010  |  Immunology

Drug-mediated and cellular immunotherapy in multiple myeloma

David S Ritchie, Hang Quach, Kate Fielding, Paul Neeson

Journal article  |  2010  |  Immunotherapy

Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients

AC Chan, P Neeson, E Leeansyah, K Tainton, H Quach, HM Prince, DI Godfrey, D Ritchie, SP Berzins

Journal article  |  2010  |  Leukemia

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

H Quach, D Ritchie, AK Stewart, P Neeson, S Harrison, MJ Smyth, HM Prince

Journal article  |  2010  |  Leukemia

In Vivo Antagonistic Effects of Dexamethasone On Lentalidomide-Induced NK Cell Activation.

Hang Quach, Hsu Andy, David Ritchie, Paul Neeson, Kevin Lynch, Simon Harrison, Miles Prince

Conference Proceedings  |  2009  |  BLOOD

Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia

Crisoula Batzios, Lachlan A Hayes, Simon Z He, Hang Quach, Zoe K McQuilten, Meaghan Wall, Lynda J Campbell

Journal article  |  2009  |  American Journal of Hematology

Safety and efficacy results from an international Expanded Access Programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients

H Quach, N Horvath, P Cannell, JR Mikhael, BE Butcher, HM Prince

Journal article  |  2009  |  Internal Medicine Journal

Lenalidomide Raises Low Regulatory T Cells in Myeloma

H Quach, D Ritchie, P Neeson, S Harrison, T Tai, K Tainton, K Lynch, HM Prince

Conference Proceedings  |  2009  |  Clinical Lymphoma and Myeloma

Predicting durable remissions following thalidomide therapy for relapsed myeloma

Hang Quach, Linda Mileshkin, John F Seymour, Alvin Milner, David Ritchie, Simon Harrison, David Westerman, H Miles Prince

Journal article  |  2009  |  Leukemia and Lymphoma

Regulatory T Cells (Treg) Are Depressed in Patients with Relapsed/Refractory Multiple Myeloma (MM) and Increases towards Normal Range in Responding Patients Treated with Lenalidomide (LEN)

Hang Quach, David Ritchie, Paul Neeson, Simon Harrison, Tsin Tai, Kellie Tainton, Kevin Lynch, Miles Prince

Conference Proceedings  |  2008  |  BLOOD

Safety and efficacy of the combination of bortezomib and dexamethasone with the deacetylase inhibitor romidepsin in patients with relapsed and refractory multiple myeloma: preliminary results of a phase I trial

HM Prince, H Quach, K Yuen, M Keegan, M Copeman, S Peinert, M Bishton, M Wolf, D Westerman, D Ritchie, JF Seymour, D Carney, SJ Harrison

Conference Proceedings  |  2008  |  BRITISH JOURNAL OF HAEMATOLOGY

In vivo tracking of dendritic cells in patients with multiple myeloma

H Miles Prince, Dominic M Wall, David Ritchie, Dirk Honemann, Simon Harrrison, Hang Quach, Mick Thompson, Rodney Hicks, Eddie Lau, Jill Davison, Maureen Loudovaris, Jude Moloney, Bruce Loveland, Jacques Bartholeyns, Andrew Katsifis, Linda Mileshkin

Journal article  |  2008  |  Journal of Immunotherapy

High-dose dexamethasone reduces bortezomib-induced thrombocytopenia

Hang Quach, Miles H Prince, Dirk Honemann, David Westerman, Alvin D Milner, Austin Barron, Simon Harrison

Conference Proceedings  |  2007  |  Blood

Safety and efficacy of the combination of bortezomib with the deacetylase inhibitor romidepsin in patients with relapsed or refractary multiple myeloma: Preliminary results of a phase I trial

Miles Prince, Hang Quach, Paul Neeson, Mitch Keegan, Michael Copeman, Stefan Peinert, Mark Bishton, Max Wolf, David Ritchie, John F Seymour, Dennis Carney, David Westerman, Simon Harrison

Conference Proceedings  |  2007  |  Blood

Prolonged progression free survival does not relate to quality of response to treatment with thalidomide in patients with relapsed multiple myeloma (MM)

Hang Quach, Miles H Prince, Linda Mileshkin, John F Seymour, David Westerman, Alvin D Milner

Conference Proceedings  |  2007  |  Blood

Treatment strategies in elderly patients with multiple myeloma: current status.

Hang Quach, H Miles Prince, Linda Mileshkin

Journal article  |  2007  |  Drugs and Aging

Multiple myeloma (MM), a plasma cell malignancy, is a disorder of the elderly with an increasing prevalence as the average life ex..

Treatment strategies in elderly patients with multiple myeloma

Hang Quach, H Miles Prince, Linda Mileshkin

Journal article  |  2007  |  Drugs & Aging

Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab.

Hang Quach, Henry Januszewicz, David Westerman

Journal article  |  2005  |  Haematologica

Hairy cell leukemia variant (HCL-v) is a rare form of a chronic B-cell lymphoproliferative disorder. Unlike typical hairy cell leu..

Effective treatment of leptomeningeal multiple myeloma with total craniospinal irradiation supported by second allogeneic donor stem cell infusion

H Quach, G Ryan, V Ganju, HM Prince

Journal article  |  2005  |  Bone Marrow Transplantation